Compare · ILMN vs TLSI
ILMN vs TLSI
Side-by-side comparison of Illumina Inc. (ILMN) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.24B, about 107.2x TLSI ($263.5M).
- TLSI has been more active in the news (9 items in the past 4 weeks vs 5 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- Illumina Inc.
- TriSalus Life Sciences Inc.
- Price
- -
- -
- Market cap
- $28.24B
- $263.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 6
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest TLSI
- TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)
- CEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)
- Szela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)
- Chief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)
- Marshak Richard increased direct ownership by 383% to 131,758 units (SEC Form 5)
- Chief Medical Officer Marshall Richard Henry was granted 60,000 shares, increasing direct ownership by 200% to 90,000 units (SEC Form 4)
- New insider Marshall Richard Henry claimed ownership of 30,000 shares (SEC Form 3)
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer